farzin farzaneh

He established the Rayne Cell and Gene Therapy Suite (RCTS) for the GMP manufacture of Investigational Medicinal Products (IMP) and Advanced Therapy Medicinal Products (ATMP) at King’s in 2001. This facility has produced the largest number of viral vectors for gene therapy based clinical studies in Europe. He is also Member of the MHRA Commission on Human Medicines: Clinical Trials, Biologicals & Vaccines (CTBV) Expert Advisory Group.

He is an honorary Consultant in Specialist Medicine at King’s College Hospital and has been authorised by the MHRA to act as a Qualified Person for the release of cell and gene therapy products for clinical trials since 2004, and acts as a QP at Guy’s and St Thomas’ Hospital, and at the Institute of Child Health / Great Ormond Street Hospital NHS Trusts, London.

Farzin is a member of the scientific advisory board of a number of biotech and pharmaceutical companies, as well as governmental and charitable scientific funding organizations. He serves as Editorial Board member on multiple scientific journals, including Experimental Biology and Medicine, for which he is the European Editor. He has published over 250 research papers with an average citation of >30 each.

In 2016, Farzin received the Distinguished Scientist Award of the US Society for Experimental Biology and Medicine.